Crossref
COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1669e ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
The FDA has warned that the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld – AstraZeneca) are unlikely to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
COVID-19HumansSARS-CoV-2Antibodies, MonoclonalDrug CombinationsAntibodies, Neutralizing
Stichwörter der Autor:innen
COVID-19Evusheldcilgavimabefficacytixagevimab
Substanzen
cilgavimab and tixagevimab drug combinationAntibodies, MonoclonalDrug CombinationsAntibodies, Neutralizing
Zitieren
APA
(2023). COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669e
Vancouver
COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669e
BibTeX
@article{euvimed2023,
title = {COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1669e}
}
EUVIMED